Alzinova AB (publ)

Stockholm Stock Exchange ALZ.ST

Alzinova AB (publ) EBIT for the year ending December 31, 2023: USD -1.63 M

Alzinova AB (publ) EBIT is USD -1.63 M for the year ending December 31, 2023, a 34.71% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Alzinova AB (publ) EBIT for the year ending December 31, 2022 was USD -2.50 M, a -201.71% change year over year.
Alzinova AB (publ) EBIT for the year ending December 31, 2021 was USD -827.88 K, a 47.45% change year over year.
Alzinova AB (publ) EBIT for the year ending December 31, 2020 was USD -1.58 M, a -19.83% change year over year.
Alzinova AB (publ) EBIT for the year ending December 31, 2019 was USD -1.31 M, a -178.93% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Stockholm Stock Exchange: ALZ.ST

Alzinova AB (publ)

CEO	Dr. Tord Labuda M.Sc., Ph.D.
IPO Date	Nov. 25, 2015
Location	Sweden
Headquarters	Pepparedsleden 1
Employees	5
Sector	Health Care
Industries Pharmaceuticals Biotechnology Vaccines

Description

Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.

Key trends

Past 5 years